BlossomHill Therapeutics (NASDAQ:BLSM) Hits New 12-Month High – Should You Buy?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) shares reached a new 52-week high on Monday . The stock traded as high as $27.99 and last traded at $27.50, with a volume of 57914 shares traded. The stock had previously closed at $25.74.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BLSM shares. HC Wainwright started coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 price objective for the company. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Leerink Partners started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 target price on the stock. Finally, Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.20.

BlossomHill Therapeutics Stock Performance

BlossomHill Therapeutics (NASDAQ:BLSM) last announced its quarterly earnings data on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). On average, equities analysts predict that BlossomHill Therapeutics, Inc. will post -3.86 EPS for the current year.

Insider Transactions at BlossomHill Therapeutics

In related news, Director John P. Schmid bought 6,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the purchase, the director owned 6,000 shares in the company, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Carl L. Gordon bought 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.